Tilray Inc (NASDAQ:TLRY - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Monday . The company traded as low as $1.42 and last traded at $1.42, with a volume of 9554855 shares changing hands. The stock had previously closed at $1.49.
Wall Street Analysts Forecast Growth
Separately, Roth Mkm decreased their target price on shares of Tilray from $2.00 to $1.75 and set a "neutral" rating for the company in a research note on Friday, October 11th.
Get Our Latest Research Report on TLRY
Tilray Stock Down 6.0 %
The firm has a market cap of $1.26 billion, a P/E ratio of -5.19 and a beta of 2.14. The business's fifty day moving average price is $1.67 and its two-hundred day moving average price is $1.78. The company has a current ratio of 2.47, a quick ratio of 1.57 and a debt-to-equity ratio of 0.08.
Tilray (NASDAQ:TLRY - Get Free Report) last announced its earnings results on Thursday, October 10th. The company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). The firm had revenue of $200.00 million for the quarter, compared to the consensus estimate of $218.70 million. Tilray had a negative net margin of 26.79% and a negative return on equity of 2.00%. The business's quarterly revenue was up 13.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.10) EPS. As a group, equities research analysts anticipate that Tilray Inc will post -0.14 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the company. Prospect Financial Services LLC bought a new position in shares of Tilray during the 2nd quarter worth about $26,000. Ferguson Wellman Capital Management Inc. acquired a new position in Tilray in the third quarter valued at about $26,000. Signature Estate & Investment Advisors LLC acquired a new position in Tilray in the second quarter valued at about $29,000. Jeppson Wealth Management LLC acquired a new position in Tilray in the second quarter valued at about $33,000. Finally, Vanguard Capital Wealth Advisors acquired a new position in Tilray in the second quarter valued at about $34,000. Institutional investors own 9.35% of the company's stock.
About Tilray
(
Get Free Report)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
Further Reading
Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
